BRKR - Bruker Corp Stock Price, Fair Value and News

78.02USD+0.26 (+0.33%)Market Closed

Market Summary

USD78.02+0.26

Market Closed

0.33%

BRKR Stock Price

View Fullscreen

BRKR RSI Chart

BRKR Valuation

Market Cap

10.7B

Price/Earnings (Trailing)

25.14

Price/Sales (Trailing)

3.62

EV/EBITDA

16.47

Price/Free Cashflow

44.17

BRKR Price/Sales (Trailing)

BRKR Profitability

Operating Margin

51.05%

EBT Margin

18.36%

Return on Equity

31.02%

Return on Assets

10.05%

Free Cashflow Yield

2.26%

BRKR Fundamentals

BRKR Revenue

Revenue (TTM)

3.0B

Rev. Growth (Yr)

20.62%

Rev. Growth (Qtr)

15.04%

BRKR Earnings

Earnings (TTM)

427.2M

Earnings Growth (Yr)

110.99%

Earnings Growth (Qtr)

133.26%

Breaking Down BRKR Revenue

Last 7 days

-9.0%

Last 30 days

-16.9%

Last 90 days

8.5%

Trailing 12 Months

-4.2%

How does BRKR drawdown profile look like?

BRKR Financial Health

Current Ratio

1.8

Debt/Equity

0.84

Debt/Cashflow

0.3

BRKR Investor Care

Dividend Yield

0.26%

Dividend/Share (TTM)

0.2

Buy Backs (1Y)

6.17%

Diluted EPS (TTM)

2.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.6B	2.7B	2.8B	3.0B
2022	2.5B	2.5B	2.5B	2.5B
2021	2.1B	2.3B	2.4B	2.4B
2020	2.0B	2.0B	2.0B	2.0B
2019	1.9B	2.0B	2.0B	2.1B
2018	1.8B	1.8B	1.9B	1.9B
2017	1.6B	1.7B	1.7B	1.8B
2016	1.6B	1.6B	1.6B	1.6B
2015	1.7B	1.7B	1.7B	1.6B
2014	1.9B	1.9B	1.9B	1.8B
2013	1.8B	1.8B	1.8B	1.8B
2012	1.7B	1.7B	1.7B	1.8B
2011	1.4B	1.5B	1.6B	1.7B
2010	1.2B	1.2B	1.3B	1.3B
2009	0	0	0	1.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bruker Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	requardt hermann fritz	sold	-1,350,900	90.0599	-15,000	-
Mar 04, 2024	requardt hermann fritz	acquired	330,750	22.05	15,000	-
Feb 28, 2024	busse falko	sold	-2,403,890	85.4808	-28,122	president, biospin group
Feb 28, 2024	busse falko	acquired	739,156	26.2839	28,122	president, biospin group
Feb 22, 2024	prause burkhard	sold	-1,276,070	83.3	-15,319	pres. & ceo, bruker best
Feb 22, 2024	prause burkhard	acquired	235,292	43.1728	5,450	pres. & ceo, bruker best
Jan 05, 2024	requardt hermann fritz	acquired	-	-	2,377	-
Jan 05, 2024	rosenthal bob	acquired	-	-	2,377	-
Jan 05, 2024	packer richard a	acquired	-	-	2,377	-
Jan 05, 2024	ma philip	acquired	-	-	2,377	-

Which funds bought or sold BRKR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	Legacy Wealth Asset Management, LLC	added	0.79	72,346	323,060	0.09%
Apr 19, 2024	First Trust Direct Indexing L.P.	new	-	233,914	233,914	0.02%
Apr 19, 2024	Covea Finance	new	-	1,268,190	1,268,190	0.06%
Apr 19, 2024	NORDEN GROUP LLC	added	2,039	8,114,550	8,422,520	0.09%
Apr 19, 2024	State of Alaska, Department of Revenue	added	0.11	820,000	3,748,000	0.04%
Apr 19, 2024	Lifestyle Asset Management, Inc.	added	1.28	268,056	1,177,440	0.70%
Apr 19, 2024	Maryland State Retirement & Pension System	unchanged	-	75,918	682,275	0.01%
Apr 19, 2024	VALLEY NATIONAL ADVISERS INC	added	66.67	1,000	2,000	-%
Apr 18, 2024	SteelPeak Wealth, LLC	new	-	688,487	688,487	0.04%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	reduced	-5.00	631	3,570	-%

Are Funds Buying or Selling BRKR?

Are funds buying BRKR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BRKR

No. of Funds

Unveiling Bruker Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	9.5%	13,192,344	SC 13G/A
Feb 13, 2024	vanguard group inc	7.15%	9,896,786	SC 13G/A
Feb 09, 2024	massachusetts financial services co /ma/	5.8%	8,080,071	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.1%	9,822,776	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	11.1%	16,368,144	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	7.51%	11,045,016	SC 13G/A
Feb 08, 2023	massachusetts financial services co /ma/	5.1%	7,513,039	SC 13G
Jan 31, 2023	blackrock inc.	7.6%	11,118,621	SC 13G/A

Recent SEC filings of Bruker Corp

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Apr 02, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Mar 01, 2024	4	Insider Trading
Feb 29, 2024	10-K	Annual Report
Feb 28, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Bruker Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.8B	40.1B	-3.17%	-4.12%	32.46	4.63	-8.12%	-17.45%
BDX	67.6B	19.5B	-4.91%	-10.36%	53.86	3.47	4.02%	-22.04%
ALGN	22.6B	3.9B	-5.82%	-15.30%	50.76	5.85	3.42%	23.09%
BAX	20.5B	14.8B	-3.67%	-10.80%	7.72	1.39	2.12%	209.17%
MID-CAP
ATR	9.3B	3.5B	-0.90%	16.36%	32.56	2.66	4.97%	18.89%
HSIC	9.3B	12.3B	-1.49%	-14.91%	22.25	0.75	-2.44%	-22.68%
BIO	8.2B	2.7B	-20.12%	-40.09%	-12.83	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.30%	-26.11%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-2.14%	10.95%	-561.38	9.3	33.86%	89.83%
PDCO	2.3B	6.6B	-4.88%	-5.43%	12	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.12%	-21.63%	-1.88	0.4	7.73%	-1066.14%
ANIK	385.8M	166.7M	2.04%	-4.03%	-4.67	2.31	6.67%	-456.34%
ANGO	250.7M	324.0M	16.79%	-29.66%	-1.3	0.77	-3.19%	-337.41%
APYX	44.0M	52.3M	1.60%	-56.21%	-2.35	0.84	17.61%	19.28%
AEMD	3.9M	3.7M	-13.45%	142.62%	-0.32	1.03	5.77%	8.23%

Bruker Corp News

Latest updates

Bruker Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	15.0%	855	743	682	685	708	639	588	595	684	609	571	555	628	511	425	424	600	521	490	461	554
Cost Of Revenue	17.8%	424	360	341	326	343	304	290	289	342	300	290	276	315	263	238	232	304	267	260	247	281
Gross Profit	12.4%	430	383	341	360	366	335	298	306	342	309	281	279	313	248	186	192	296	254	230	215	273
Operating Expenses	26.5%	327	258	254	237	235	204	224	210	216	196	195	190	200	167	148	176	179	166	177	173	166
S&GA Expenses	18.9%	211	178	178	163	165	145	152	146	153	141	135	132	130	115	102	121	130	125	125	120	117
R&D Expenses	17.1%	84.00	71.00	71.00	69.00	64.00	56.00	60.00	57.00	58.00	52.00	56.00	55.00	57.00	48.00	44.00	49.00	47.00	46.00	49.00	46.00	45.00
EBITDA Margin	-	0.23*	-	0.20*	0.21*	0.21*	0.21*	0.20*	0.21*	0.21*	0.21*	0.20*	0.19*	0.17*	-	-	-	-	-	-	-	-
Income Taxes	20.5%	37.00	31.00	20.00	30.00	23.00	41.00	20.00	32.00	44.00	21.00	21.00	28.00	34.00	20.00	7.00	3.00	42.00	22.00	11.00	8.00	22.00
Earnings Before Taxes	102.1%	241	119	78.00	107	121	129	70.00	94.00	120	109	80.00	85.00	106	75.00	31.00	14.00	111	83.00	48.00	38.00	100
EBT Margin	21.9%	0.18*	0.15*	0.16*	0.16*	0.16*	0.16*	0.16*	0.16*	0.16*	0.16*	0.15*	0.14*	-	-	-	-	-	-	-	-	-
Net Income	133.3%	206	88.00	57.00	77.00	97.00	88.00	50.00	62.00	76.00	87.00	58.00	57.00	69.00	54.00	24.00	11.00	69.00	61.00	37.00	31.00	78.00
Net Income Margin	27.3%	0.14*	0.11*	0.12*	0.12*	0.12*	0.11*	0.11*	0.11*	0.11*	0.11*	0.10*	0.10*	-	-	-	-	-	-	-	-	-
Free Cashflow	911.6%	174	17.00	-10.50	63.00	137	12.00	-62.30	59.00	110	8.00	-0.70	73.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	11.3%	4,250	3,820	3,857	3,764	3,612	3,337	3,385	3,551	3,650	3,128	3,087	3,035	3,049	2,879	2,943	2,962	2,772	2,352	2,350	2,243	2,129
Current Assets	6.6%	2,164	2,029	2,183	2,133	2,113	2,037	2,088	2,251	2,472	1,989	1,968	1,946	1,925	1,826	1,957	1,990	1,796	1,434	1,406	1,344	1,304
Cash Equivalents	34.3%	488	364	575	598	646	629	726	820	1,072	577	612	700	686	571	750	799	682	300	287	303	326
Inventory	5.7%	968	916	915	859	800	750	759	740	710	733	730	701	692	696	665	626	577	587	595	542	510
Net PPE	13.8%	600	527	523	511	487	422	395	404	406	389	398	384	396	355	336	319	306	278	282	268	271
Goodwill	3.8%	583	561	558	527	458	382	396	384	340	324	315	313	320	313	295	290	293	282	285	6.00	276
Liabilities	-	2,837	-	-	-	2,480	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	12.1%	1,202	1,072	1,051	1,049	914	865	818	881	939	921	955	944	792	683	750	766	646	643	641	633	599
Long Term Debt	5.6%	1,160	1,099	1,123	1,109	1,201	1,137	1,171	1,205	1,222	718	721	716	842	828	924	915	813	519	494	332	323
LT Debt, Non Current	5.6%	1,160	1,099	1,123	1,109	1,201	1,137	1,171	1,205	1,222	718	721	716	842	828	924	915	813	519	494	-	323
Shareholder's Equity	13.9%	1,377	1,209	1,251	1,199	1,114	948	984	1,031	1,085	1,090	1,015	982	974	963	907	925	917	855	870	922	905
Retained Earnings	-	2,324	-	-	-	1,926	-	-	-	1,660	-	-	-	1,407	-	-	-	1,275	-	-	-	1,103
Additional Paid-In Capital	-	283	-	-	-	256	-	-	-	238	-	-	-	216	-	-	-	200	-	-	-	177
Shares Outstanding	-0.5%	145	146	147	147	147	147	148	149	151	152	151	152	-	-	-	-	-	-	-	-	-
Minority Interest	-4.9%	17.00	18.00	20.00	19.00	12.00	11.00	14.00	14.00	14.00	14.00	13.00	14.00	13.00	11.00	9.00	9.00	10.00	10.00	9.00	8.00	9.00
Float	-	-	-	6,099	-	-	-	4,001	-	-	-	4,040	-	-	-	2,173	-	-	-	5,068	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	366.0%	205,500	44,100	13,000	87,500	171,500	69,500	-44,400	77,800	138,600	23,900	21,900	98,000	203,000	82,400	11,800	35,000	136,200	52,400	10,600	14,200	132,300
Share Based Compensation	8.8%	6,200	5,700	5,600	6,500	4,700	5,300	9,700	8,000	5,300	4,200	3,900	3,800	5,100	4,500	3,100	3,300	-500	4,000	3,000	3,100	3,100
Cashflow From Investing	76.3%	-36,800	-155,000	-26,000	-108,200	-149,300	-57,600	57,100	-101,800	-48,600	-48,400	-71,400	-24,000	-28,800	-48,200	-15,100	-100,600	-39,200	-12,600	-79,900	-26,700	-156,300
Cashflow From Financing	35.2%	-59,900	-92,500	-10,300	-30,700	-36,100	-82,000	-79,800	-217,400	404,300	-2,600	-44,900	-38,100	-74,300	-225,500	-53,100	191,300	277,900	-19,500	50,400	-8,800	76,600
Dividend Payments	-1.4%	7,300	7,400	7,300	7,400	7,400	7,400	7,500	7,500	6,000	6,100	6,000	6,100	6,100	6,200	6,100	6,200	6,200	6,200	6,300	6,300	6,300
Buy Backs	-37.2%	50,400	80,300	100	22,300	25,550	72,400	60,300	105,600	82,200	-	38,300	32,800	68,800	5,000	50,000	-	-	42,300	100,000	-	-

BRKR Income Statement

2023-12-31

Statement - CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 2,964.5	$ 2,530.7	$ 2,417.9
Total cost of revenue	1,451.2	1,225.0	1,208.3
Gross profit	1,513.3	1,305.7	1,209.6
Operating expenses:
Selling, general and administrative	729.4	607.4	561.2
Research and development	294.8	235.9	220.8
Other charges, net	52.2	29.7	14.3
Total operating expenses	1,076.4	873.0	796.3
Operating income	436.9	432.7	413.3
Bargain purchase gain	144.1	0.0	0.0
Interest and other income (expense), net	(36.8)	(18.8)	(19.7)
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries	544.2	413.9	393.6
Income tax provision	117.7	116.4	113.0
Equity in income of unconsolidated investees, net of tax	2.0	1.0	0.0
Consolidated net income	428.5	298.5	280.6
Net income attributable to noncontrolling interests in consolidated subsidiaries	1.3	1.9	3.5
Net income attributable to Bruker Corporation	$ 427.2	$ 296.6	$ 277.1
Net income per common share attributable to Bruker Corporation shareholders:
Basic	$ 2.92	$ 2	$ 1.83
Diluted	$ 2.9	$ 1.99	$ 1.81
Weighted average common shares outstanding:
Basic	146.4	148.6	151.4
Diluted	147.2	149.4	152.9
Product
Total revenue	$ 2,457.6	$ 2,109.9	$ 2,017.3
Total cost of revenue	1,165.2	984.0	979.3
Service
Total revenue	493.8	414.6	393.2
Total cost of revenue	285.9	240.8	228.2
Other
Total revenue	13.1	6.2	7.4
Total cost of revenue	$ 0.1	$ 0.2	$ 0.8

BRKR Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 488.3	$ 645.5
Accounts receivable, net	492.0	472.7
Inventories	968.3	800.1
Assets held for sale	0.0	1.4
Other current assets	215.6	193.5
Total current assets	2,164.2	2,113.2
Property, plant and equipment, net	599.7	487.0
Goodwill	582.6	457.6
Intangible assets, net	330.5	270.9
Operating lease assets	91.7	51.2
Deferred tax assets	297.2	76.8
Other long-term assets	184.0	155.1
Total assets	4,249.9	3,611.8
Current liabilities:
Current portion of long-term debt	121.2	18.7
Accounts payable	202.7	178.4
Deferred revenue and customer advances	400.0	370.2
Other current liabilities	478.2	347.0
Total current Liabilities	1,202.1	914.3
Long-term debt	1,160.3	1,200.5
Long-term deferred revenue and customer advances	91.5	101.6
Deferred tax liabilities	67.7	62.3
Operating lease liabilities	74.8	34.8
Accrued pension	76.6	45.7
Other long-term liabilities	163.6	120.8
Total Liabilities	2,836.6	2,480.0
Commitments and contingencies (Note 18)
Redeemable noncontrolling interests	18.7	6.1
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding at December 31, 2023 and 2022	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,943,705 and 175,389,586 shares issued and 145,164,826 and 147,023,144 outstanding at December 31, 2023 and 2022, respectively	1.7	1.7
Treasury stock at cost, 30,778,879 and 28,366,442 shares at December 31, 2023 and 2022, respectively	(1,237.2)	(1,085.0)
Additional paid-in capital	282.9	256.3
Retained earnings	2,323.8	1,926.0
Accumulated other comprehensive income, net of tax	6.0	14.8
Total shareholders' equity attributable to Bruker Corporation	1,377.2	1,113.8
Noncontrolling interests in consolidated subsidiaries	17.4	11.9
Total shareholders' equity	1,394.6	1,125.7
Total liabilities, redeemable noncontrolling interest and shareholders' equity	$ 4,249.9	$ 3,611.8

About Bruker Corp

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

CEO	Dr. Frank H. Laukien Ph.D.
WEBSITE	bruker.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	8525

Bruker Corp Frequently Asked Questions

What is the ticker symbol for Bruker Corp? What does BRKR stand for in stocks?

BRKR is the stock ticker symbol of Bruker Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bruker Corp (BRKR)?

As of Mon Apr 22 2024, market cap of Bruker Corp is 10.74 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BRKR stock?

You can check BRKR's fair value in chart for subscribers.

What is the fair value of BRKR stock?

You can check BRKR's fair value in chart for subscribers. The fair value of Bruker Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bruker Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BRKR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bruker Corp a good stock to buy?

The fair value guage provides a quick view whether BRKR is over valued or under valued. Whether Bruker Corp is cheap or expensive depends on the assumptions which impact Bruker Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BRKR.

What is Bruker Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, BRKR's PE ratio (Price to Earnings) is 25.14 and Price to Sales (PS) ratio is 3.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BRKR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bruker Corp's stock?

In the past 10 years, Bruker Corp has provided 0.142 (multiply by 100 for percentage) rate of return.